Sherry A Wuensch1, Jessica Spahn, Ian N Crispe. 1. The David H. Smith Center for Vaccine Biology and Immunology, University of Rochester Medical Center, Rochester, NY, USA.
Abstract
UNLABELLED: Both hepatitis B and C viruses frequently establish chronic infection, raising the question whether T cells are poorly primed in the liver. To determine the role of different cell types in the activation of CD8+ T cells against hepatocellular antigens, we used an Adeno-associated virus to deliver ovalbumin to hepatocytes. In contrast to CD8+ T cells, CD4+ T cells were not activated. The CD8+ T cells were activated even in the absence of endogenous CD4+ T cells; however, in the liver, these cells were high in the programmed death-1 protein and low in CD127. Chimera experiments revealed that these CD8+ T cells were activated on a solid tissue cell. CONCLUSION: Priming of CD8+ T cells directly on nonhematopoietic cells, in the absence of CD4+ T cell help, results in suboptimal T cell activation. This could explain the impaired function of CD8+ T cells seen in chronic liver infection.
UNLABELLED: Both hepatitis B and C viruses frequently establish chronic infection, raising the question whether T cells are poorly primed in the liver. To determine the role of different cell types in the activation of CD8+ T cells against hepatocellular antigens, we used an Adeno-associated virus to deliver ovalbumin to hepatocytes. In contrast to CD8+ T cells, CD4+ T cells were not activated. The CD8+ T cells were activated even in the absence of endogenous CD4+ T cells; however, in the liver, these cells were high in the programmed death-1 protein and low in CD127. Chimera experiments revealed that these CD8+ T cells were activated on a solid tissue cell. CONCLUSION: Priming of CD8+ T cells directly on nonhematopoietic cells, in the absence of CD4+ T cell help, results in suboptimal T cell activation. This could explain the impaired function of CD8+ T cells seen in chronic liver infection.
Authors: Ingo Klein; Judith C Cornejo; Noelle K Polakos; Beena John; Sherry A Wuensch; David J Topham; Robert H Pierce; Ian Nicholas Crispe Journal: Blood Date: 2007-08-09 Impact factor: 22.113
Authors: Henry Radziewicz; Chris C Ibegbu; Marina L Fernandez; Kimberly A Workowski; Kamil Obideen; Mohammad Wehbi; Holly L Hanson; James P Steinberg; David Masopust; E John Wherry; John D Altman; Barry T Rouse; Gordon J Freeman; Rafi Ahmed; Arash Grakoui Journal: J Virol Date: 2006-12-20 Impact factor: 5.103
Authors: Nathalie Labarrière; Laurent Bretaudeau; Nadine Gervois; Marie Bodinier; Gwenola Bougras; Elisabeth Diez; François Lang; Marc Gregoire; Francine Jotereau Journal: Int J Cancer Date: 2002-09-20 Impact factor: 7.396
Authors: Eric Dobrzynski; Federico Mingozzi; Yi-Lin Liu; Elisabeth Bendo; Ou Cao; Lixin Wang; Roland W Herzog Journal: Blood Date: 2004-04-22 Impact factor: 22.113
Authors: F Lechner; D K Wong; P R Dunbar; R Chapman; R T Chung; P Dohrenwend; G Robbins; R Phillips; P Klenerman; B D Walker Journal: J Exp Med Date: 2000-05-01 Impact factor: 14.307
Authors: Dimitra Peppa; Upkar S Gill; Gary Reynolds; Nicholas J W Easom; Laura J Pallett; Anna Schurich; Lorenzo Micco; Gaia Nebbia; Harsimran D Singh; David H Adams; Patrick T F Kennedy; Mala K Maini Journal: J Exp Med Date: 2012-12-17 Impact factor: 14.307